About: A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose
Creator	Douglas, Trevor Harmsen, Ann Rynda-Apple, Agnieszka Harmsen, Allen Richert, Laura Han, Soo Servid, Amy Wiley, James
Source	Elsevier; Medline; PMC
abstract	We show that a model antigen, ovalbumin (OVA), can be chemically conjugated to the exterior of a small heat shock protein (sHsp) cage that has structural similarities to virus-like particles (VLPs). OVA-sHsp conjugation efficiency was dependent upon the stoichiometry and the length of the small molecule linker utilized, and the attachment position on the sHsp cage. When conjugated OVA-sHsp was delivered intranasally to naïve mice, the resulting immune response to OVA was accelerated and intensified, and OVA-specific IgG1 responses were apparent within 5 days after a single immunizing dose, illustrating its utility for vaccine development. If animals were pretreated with a disparate VLP, P22 (a non-replicative bacteriophage capsid), before OVA-sHsp conjugate immunization, OVA-specific IgG1 responses were apparent already by 4 days after a single immunizing dose of conjugate in OVA-naïve mice. Additionally, the mice pretreated with P22 produced high titer mucosal IgA, and isotype-switched OVA-specific serum IgG. Similarly, sHsp pretreatment enhanced the accumulation of lung germinal center B cells, T follicular helper cells, and increased polymeric Ig receptor expression, priming the lungs for subsequent IgG and IgA responses to influenza virus challenge. Thus, sHsp nanoparticles elicited quick and intense antibody responses and these accelerated responses could similarly be induced to antigen chemically conjugated to the sHsp. Pretreatment of mice with P22 further accelerated the onset of the antibody response to OVA-sHsp, demonstrating the utility of conjugating antigens to VLPs for pre-, or possibly post-exposure prophylaxis of lung, all without the need for adjuvant.
has issue date	2012-05-01(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2012.03.035
bibo:pmid	22465748
has license	green-oa
sha1sum (hex)	ab7acd1a5a78ec6d3f6cdddd26fb6f3923e3e371
schema:url	https://doi.org/10.1016/j.vaccine.2012.03.035
resource representing a document's title	A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose
has PubMed Central identifier	PMC3579574
has PubMed identifier	22465748
schema:publication	Vaccine
resource representing a document's body	covid:ab7acd1a5a78ec6d3f6cdddd26fb6f3923e3e371#body_text
is schema:about of	named entity 'MUCOSAL' named entity 'utility' named entity 'heat shock protein' named entity 'apparent' named entity 'conjugated' named entity 'When' named entity 'priming' named entity 'Public Access' named entity 'Author' named entity 'Manuscript' named entity 'vaccine' named entity 'single' named entity 'DOSE' named entity 'ANTIBODY RESPONSE' named entity 'IGA' named entity 'SPECIFIC' named entity 'INTENSE' named entity 'SERUM' named entity 'PROPHYLAXIS OF' named entity 'CONJUGATED' named entity 'IGG1' named entity 'MICE' named entity 'SINGLE' named entity 'IMMUNIZATION' named entity 'POLYMERIC' named entity 'EXTERIOR' named entity 'ANIMALS' named entity 'BACTERIOPHAGE' named entity 'LUNG' named entity 'DELIVERED' named entity 'SMALL HEAT SHOCK PROTEIN' named entity 'TITER' named entity 'QUICK' named entity 'PRE' named entity 'THE LUNGS' named entity 'CONJUGATE' named entity 'VACCINE DEVELOPMENT' named entity 'SMALL MOLECULE' named entity 'RESPONSE TO' named entity 'ELICITED' named entity 'ENHANCED' named entity 'CAPSID' named entity 'PRETREATMENT' named entity 'ACCESS' named entity 'CONJUGATION' named entity 'VLP' named entity 'OVALBUMIN' named entity 'VLPS' named entity 'SUBSEQUENT' named entity 'CHEMICALLY' named entity 'PROTEIN ' named entity 'CHALLENGE' named entity 'THESE' named entity 'NEED FOR' named entity 'RECEPTOR EXPRESSION' named entity 'EFFICIENCY' named entity 'HIGH' named entity 'CAGE' named entity 'ADJUVANT' named entity 'ANTIBODY' named entity 'STRUCTURAL' named entity 'APPARENT' named entity 'POST-EXPOSURE PROPHYLAXIS' named entity 'UTILITY' covid:arg/ab7acd1a5a78ec6d3f6cdddd26fb6f3923e3e371 named entity 'RESULTING' named entity 'ANTIGENS' named entity 'B CELLS' named entity 'STOICHIOMETRY' named entity '28A' named entity 'T FOLLICULAR HELPER CELLS' named entity 'DEPENDENT' named entity 'PRIMING' named entity 'LUNG'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software